Neurochemical and behavioural features induced by chronic low dose treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset: Implications for Parkinson's disease?

Neuroscience Letters

Volumn 123, Issue 1, 1991, Pages 115-118

  Russ, Hermann ^a   Mihatsch, Walter ^a   Gerlach, Manfred ^a,b   Riederer, Peter ^b   Przuntek, Horst ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

1 Methyl 4 phenyl 1,2,3,6 tetrahydropyridine (MPTP); Callithrix jacchus; Marmoset; Neurotransmitter metabolism; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; BIOGENIC AMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; LOCOMOTION; MALE; MONKEY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 3,4-DIHYDROXYPHENYLACETIC ACID; ANIMAL; BIOGENIC AMINES; BRAIN; CALLITRICHINAE; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HOMOVANILLIC ACID; HYDROXYINDOLEACETIC ACID; MALE; MOTOR ACTIVITY; MPTP POISONING; NOREPINEPHRINE; PARKINSON DISEASE; POSTURE; SEROTONIN; SUBSTANTIA NIGRA; SUPPORT, NON-U.S. GOV'T;

EID: 0026099265     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/0304-3940(91)90171-O     Document Type: Article

References (23)

1. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases
2. Brain dopamine and the syndromes of Parkinson and Huntington
3. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
4. The clinical syndrome of striatal dopamine deficiency: parkinsonism in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
5. Biochemical aids in the diagnosis of Parkinson's disease
6. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on catecholamines and metabolites in primate brain and CSF
7. Suboccipital puncture for cerebrospinal fluid in the common marmoset (Callithrix jacchus)
8. The evolution and distribution of morphological changes in the nervous system of the common marmoset following the acute administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
9. The neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its relevance to Parkinson's disease
10. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease: pathophysiologic and clinical implications
11. Mechanism of MPTP toxicity: more answers, more questions
12. The etiology of Parkinson's disease: new directions for research
13. Protein measurement with the Folin phenol reagent
14. Altered serotonin metabolism in depressed patients with Parkinson's disease
15. Time course of nigrostriatal degeneration in Parkinson's disease
16. Responses of neurons in different regions of the striatum of the behaving monkey
17. The MPTP-model: an update
18. Protection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism by the catecholamine uptake inhibitor nomifensine: behavioral analyses of monkeys with partial striatal dopamine depletions
19. Levels of met-enkephalin leu-enkephalin substance P and cholecystokinin in the brain of the common marmoset following long term 1-methyl-4-phenyl-1236-tetrahydropyridine treatment
20. Correlation of autonomic dysfunction to CSF concentrations of noradrenaline and 3-methoxy-4-hydroxyphenylglycol in Parkinson's disease
21. Simultaneous determination of 3,4-dihydroxyphenylalanine, 5-hydroxytryptophan, dopamine, 4-hydroxy-3-methoxyphenylalanine, norepinephrine, 3,4-dihydroxyphenylacetic acid, homovanillic acid, serotonin, and 5-hydroxyindole acetic acid in rat cerebrospinal fluid and brain by high performance liquid chromatography with electrochemical detection
22. MPTP, impairment of motor performance and amine accumulation in Macaca fascicularis